NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional)

Funder: National Institutes of Health

Due Date: 9/7/2020

Budget: $2,000,000

Opportunity: RFA-DA-18-020

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-18-020.html

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use.  Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.

The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 will support a project with specific milestones to be accomplished at the end of the 2-year period. The UH3 will provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases.

Through this FOA, NIDA seeks to attract exceptionally talented investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing.

Leave a Reply